• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2018 Dec 11. doi: 10.1111/irv.12624. [Epub ahead of print]
[h=1]Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.[/h] Chong Y[SUP]1[/SUP], Matsumoto S[SUP]2[/SUP], Kang D[SUP]2,[/SUP][SUP]3[/SUP], Ikematsu H[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The large consumption of neuraminidase (NA) inhibitors (NAIs) for the treatment of influenza virus infections places Japan at risk of becoming the epicenter of the global spread of NAI-resistant viruses.
[h=4]OBJECTIVE:[/h] To clarify NA amino acid mutations of epidemic influenza viruses in Japan and their related NAI resistance METHODS: A total of 1791 samples, including 396 A/H1N1pdm09, 1117 A/H3N2, and 278 B isolates, were collected to determine of their 50% inhibitory concentration (IC[SUB]50[/SUB] ) values by NAIs (oseltamivir, zanamivir, peramivir, and laninamivir) during the Japanese seasons from 2011-12 to 2016-17. Then, 380 samples including 49 A/H1N1pdm09, 251 A/H3N2, and 80 B isolates, were sequenced for the entire NA genes.
[h=4]RESULTS:[/h] NAI-resistant A/H1N1pdm09 viruses were detected at a frequency of 1.3% (5/396 isolates) in the epidemic seasons. None of the A/H3N2 and B viruses developed resistance to any of the four NAIs during the six seasons. Only five and 13 AA mutations were detected in the NA catalytic sites of A/H1N1pdm09 and A/H3N2 viruses, respectively. No mutations were observed in the catalytic sites of B viruses. Four of the five mutations in the catalytic sites of A/H1N1pdm09 consisted of H275Y, which was related to high resistance to oseltamivir and peramivir. Most (10/13) of the catalytic site mutations in A/H3N2 were associated with MDCK-passaged induction (D151G/N). Finally, no mutations related to substantial NAI resistance were detected in the A/H3N2 and B viruses examined.
[h=4]CONCLUSION:[/h] These findings suggest that the NA catalytic sites of influenza viruses are well preserved. Even in Japan, no spread of NAI-resistant viruses has been observed, and A/H1N1pdm09 viruses carrying H275Y remain limited. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Influenza; mutation; neuraminidase; neuraminidase inhibitor; resistance

PMID: 30548432 DOI: 10.1111/irv.12624
 
Back
Top Bottom